Trials / Completed
CompletedNCT01741727
A Study of ABT-414 in Subjects With Solid Tumors
A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumors Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
A study of ABT-414 in subjects with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-414 | ABT-414 will be administered by intravenous infusion. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2012-12-05
- Last updated
- 2017-11-20
Locations
6 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01741727. Inclusion in this directory is not an endorsement.